BioStock: SynAct Pharma’s CEO comments on the recent progress

SynAct Pharma recently achieved a milestone by completing dosing in the Phase IIb EXPAND study for resomelagon (AP1189), their candidate targeting rheumatoid arthritis. In addition, the company has now also successfully recruited all patients for part A of the Phase IIa/b RESOLVE study. To delve deeper into these developments, BioStock contacted SynAct Pharma’s CEO, Torbjørn Bjerke, for a comment.

Read the full interview with Torbjørn Bjerke at biostock.se:

https://www.biostock.se/en/2023/07/synact-pharmas-ceo-comments-on-the-recent-progress/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/